Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts

More about Open Access at the Crick

Abstract

BACKGROUND & AIMS: Colorectal cancer (CRC) shows variable response to immune checkpoint blockade, which can only partially be explained by high tumour mutational burden (TMB). We conducted an integrated study of the cancer tissue and associated tumour microenvironment (TME) from patients treated with Pembrolizumab (KEYNOTE 177 clinical trial) or Nivolumab to dissect the cellular and molecular determinants of response to anti-PD1 immunotherapy. METHODS: We selected multiple regions per tumour showing variable T cell infiltration for a total of 738 regions from 29 patients, divided into discovery and validation cohorts. We performed multi-regional whole exome and RNA sequencing of the tumour cells and integrated these with T-cell receptor sequencing, high-dimensional imaging mass cytometry, detection of PD1-PDL1 interaction in situ, multiplexed immunofluorescence, and computational spatial analysis of the TME. RESULTS: In hypermutated CRCs, response to anti-PD1 immunotherapy was not associated with TMB but with high clonality of immunogenic mutations, clonally expanded T cells, low activation of WNT signalling, deregulation of the interferon gamma pathway and active immune escape mechanisms. Responsive hypermutated CRCs were also rich in cytotoxic and proliferating PD1+CD8 T cells interacting with PDL1+ antigen-presenting macrophages. CONCLUSIONS: Our study clarified the limits of TMB as a predictor of response of CRC to anti-PD1 immunotherapy. It identified a population of antigen-presenting macrophages interacting with CD8 T cells that consistently segregate with response. We therefore concluded that anti-PD1 agents release the PD1-PDL1 interaction between CD8 T cells and macrophages to promote cytotoxic anti-tumour activity.

Crick authors

Crick First author
Crick Corresponding author